Ovid Therapeutics (OVID)
2.40
-0.08 (3.23%)
Upcoming Events
Latest Headlines
Ovid Therapeutics to Participate in Upcoming Investor Conferences
June 4, 2026 7:00 AM - StreetInsider
Form 8-K Ovid Therapeutics Inc. For: May 29
June 3, 2026 7:03 AM - SEC Filing
Ovid Therapeutics names Anna Greka to board of directors
June 3, 2026 7:00 AM - StreetInsider
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
June 3, 2026 7:00 AM - StreetInsider
Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC
May 15, 2026 11:58 AM - SEC Filing
Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: Sirenia Capital Management LP
May 15, 2026 8:04 AM - SEC Filing
Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
May 15, 2026 6:36 AM - SEC Filing
Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M
May 14, 2026 4:29 PM - SEC Filing
Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: Affinity Asset Advisors, LLC
May 14, 2026 4:19 PM - SEC Filing
B.Riley Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
May 13, 2026 4:16 AM - StreetInsider
Ovid Therapeutics Inc. (OVID) Reports In-Line Q1 EPS
May 12, 2026 7:26 AM - StreetInsider
Form 10-Q Ovid Therapeutics Inc. For: Mar 31
May 12, 2026 7:07 AM - SEC Filing
Form 8-K Ovid Therapeutics Inc. For: May 12
May 12, 2026 7:04 AM - SEC Filing
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 12, 2026 7:01 AM - Globe NewsWire
Form ARS Ovid Therapeutics Inc. For: Dec 31
April 27, 2026 5:13 PM - SEC Filing
Form DEFA14A Ovid Therapeutics Inc.
April 27, 2026 5:12 PM - SEC Filing
Form DEF 14A Ovid Therapeutics Inc. For: Dec 31
April 27, 2026 5:11 PM - SEC Filing
Form 424B3 Ovid Therapeutics Inc.
April 27, 2026 5:01 PM - SEC Filing
Form EFFECT Ovid Therapeutics Inc.
April 27, 2026 6:04 AM - SEC Filing
Ovid Therapeutics (OVID) files for 29.86M share offering by selling stockholders
April 21, 2026 4:35 PM - StreetInsider
Form S-3 Ovid Therapeutics Inc.
April 21, 2026 4:32 PM - SEC Filing
Form 8-K Ovid Therapeutics Inc. For: Apr 17
April 20, 2026 8:18 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
April 20, 2026 6:39 AM - StreetInsider
Leerink Partners stays Outperform on Ovid Therapeutics Inc (OVID) following KCC2 R&D Day
April 15, 2026 11:16 AM - StreetInsider
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: PAPADOPOULOS STELIOS
April 9, 2026 5:15 PM - SEC Filing
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Fitzgerald Kevin Joseph
April 9, 2026 5:15 PM - SEC Filing
Form 4 Ovid Therapeutics Inc. For: Apr 07 Filed by: Friedman Bart
April 9, 2026 5:15 PM - SEC Filing
Ovid Therapeutics Inc (OVID) PT Raised to $4 at H.C. Wainwright
April 9, 2026 6:40 AM - StreetInsider
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
April 8, 2026 8:01 AM - Globe NewsWire
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
April 8, 2026 8:01 AM - StreetInsider
Form 4 Ovid Therapeutics Inc. For: Mar 23 Filed by: LEVIN JEREMY M
March 25, 2026 9:18 PM - SEC Filing
B.Riley Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
March 20, 2026 4:50 AM - StreetInsider
Leerink Partners stays Outperform on Ovid Therapeutics Inc (OVID): Ph2 'solid probability of success'
March 19, 2026 3:07 PM - StreetInsider
Ovid Therapeutics Inc (OVID) PT Raised to $5 at Roth/MKM
March 19, 2026 10:28 AM - StreetInsider
Form S-8 Ovid Therapeutics Inc.
March 18, 2026 4:49 PM - SEC Filing
Form 10-K Ovid Therapeutics Inc. For: Dec 31
March 18, 2026 4:27 PM - SEC Filing
Form 8-K Ovid Therapeutics Inc. For: Mar 17
March 18, 2026 7:39 AM - SEC Filing
Ovid Therapeutics advances OV329 epilepsy drug, secures $60M funding
March 18, 2026 6:05 AM - StreetInsider
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
March 18, 2026 6:05 AM - StreetInsider
Ovid Therapeutics prices $60 million private placement for drug development
March 18, 2026 6:00 AM - StreetInsider
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
March 18, 2026 6:00 AM - StreetInsider
Full Article List
